Financial overview
Second quarter, April 1 - June 30, Q2 2025
(Figures in parentheses refer to the corresponding period in the previous year.)

• Net sales amounted to 0 (0).
• Other operating income amounted to 946 (18) thousand SEK.
• Profit after tax amounted to -12,740 (-11,224) thousand SEK.
• Earnings per share before and after dilution: -0.02 (-0.02) SEK.
• Cash flow from operating activities was -4,699 (-88) thousand SEK.

First half of the year, January 1 – June 30, 2025
(Figures in parentheses refer to the corresponding period in the previous year.)

• Net sales amounted to 0 (0).
• Other operating income amounted to 2,608 (86) thousand SEK.
• The profit after tax amounted to –23,676 (-20,152) thousand SEK.
• Earnings per share before and after dilution: -0.03 (-0.04) SEK.
• Cash flow from operating activities was -13,875 (-8,888) thousand SEK.

Significant events during the quarter

• Study demonstrated rapid biomarker integration on Psyros™ POC platform

A joint research project between Prolight and cardiologist Dr. Sam McGrath at St Thomas’ Hospital demonstrated how quickly a test for the cardiac biomarker cMyC can be transferred to the Psyros POC system. The study highlighted the platform’s potential and its broader diagnostic applications beyond high-sensitivity troponin.

• Prolight granted its first two European patents for Psyros technology

The company’s first two European patents for Psyros technology for single-molecule counting were granted by the European Patent Office (EPO). The patents are valid until 2040 and 2041, respectively.

• Prolight granted new MicroFlex patent in the U.S.

The U.S. Patent and Trademark Office approved Prolight’s patent for the analytical unit and reaction chamber of its MicroFlex point-of-care diagnostic system.

• Prolight resolved on a rights issue

At an extraordinary general meeting on June 10, 2025, Prolight resolved to carry out a rights issue of SEK 100.3 million. The subscription period ran from June 16 to June 30, 2025. The proceeds are intended to complete the development of the Psyros system.

• New chairman of the board

Fredrik Alpsten was elected as a new board member and Chairman of the Board at the Annual General Meeting on June 30, 2025.

• Prolight announced positive data from patient blood study at St Thomas’ Hospital, London

Initial data from St Thomas’ Hospital confirmed the equivalence between whole blood and plasma in patients with elevated troponin levels. The study is an important step between the successful biobank study earlier this year and the planned regulatory clinical performance study.

Significant events after the end of the period

• Prolight’s rights issue fully subscribed

The rights issue was fully subscribed, with approximately 70.2 percent subscribed with subscription rights and about 29.8 percent without subscription rights. The net proceeds from the issue amount to approximately SEK 100.3 million before issuance costs and offsets. The new shares are now registered with the Swedish Companies Registration Office and delivered to the respective investors.

• Prolight received patent approval in Japan for core Psyros patent

Prolight Diagnostics was granted a patent for its Psyros single-molecule counting technology in Japan from the Japan Patent Office (JPO). The patent is valid until 2040.

• Prolight showcased Psyros at ADLM 2025 in Chicago

Prolight showcased for the first time a fully functioning commercial prototype of its groundbreaking point-of-care system, Psyros at the international congress Association for Diagnostics & Laboratory Medicine (ADLM) 2025, held in Chicago from July 27–29.

• Prolight receives Notice of Intention to Grant in Europe for third Psyros patent

The European Patent Office (EPO) has issued a Notice of Intention to Grant for the company’s third patent application related to its proprietary Psyros single-molecule-counting technology.

CEO statement
Successful study results, strengthened financial position, and record interest from global partners

During the second quarter, we made decisive progress in the commercialization of our groundbreaking point-of-care (POC) diagnostic platform, with the high-sensitivity troponin test set to be the first product launched. With intial positive results from our whole blood study, a fully subscribed rights issue, and record interest from potential international commercial partners, we are now stronger than ever.

A key achievement during the quarter was the initial results from the ongoing whole blood study at St Thomas’ Hospital in London. The results show clear equivalence between whole blood and plasma, confirming that our Psyros POC system delivers the same high clinical performance regardless of sample type. This is another important milestone that reduces the risks for the planned clinical performance study required for regulatory approval in the EU and further strengthens our position in discussions with potential commercial partners.

At the same time, we secured our financial position through a fully subscribed rights issue – with strong participation from the board, management, and ITL, our contract manufacturing partner for the instrument. The high level of commitment demonstrates strong confidence in the company and our strategy, enabling cost-effective financing without the need for underwriters. The capital raised gives us the flexibility we need to successfully complete development, intensify commercial partner discussions, and initiate the regulatory clinical performance study in 2025, without financial pressure.

During the quarter, we also welcomed our new chairman of the board, Fredrik Alpsten. With extensive experience from senior positions in international diagnostics, our new chairman brings valuable expertise and a strong network to help take Psyros to the global market.

Our presence at the international congress ADLM (Association for Diagnostics & Laboratory Medicine & Clinical Lab Expo) in Chicago at the end of July was a milestone in itself. Our fully operational commercial prototype attracted substantial international attention – many visitors took the opportunity to explore the system firsthand and experience its performance and ease of use. Interest has grown significantly following the positive results from our biobank and whole blood studies, confirming that our solution is perfectly timed for the market. Meeting potential commercial partners and future users who could personally witness the system’s performance and usability was both rewarding and inspiring.

Overall, the second quarter has been marked by successful scientific results, a strengthened financial foundation, and growing interest from commercial partners. Combined with our unique, proprietary POC technology – which enables single-molecule counting in a portable format – a strong IP portfolio (further strengthened during the quarter), and a dedicated team, we are now well equipped for the continued journey toward commercialization.

We continue to create value for our shareholders by providing fast, accurate point of care system that contribute to quicker diagnoses and appropriate treatment that saves lives.

Lund August 28 2025
Ulf Bladin
CEO Prolight Diagnostics (publ)